Sagent Pharmaceuticals, a privately held specialty pharmaceutical company, has acquired Infusive Technologies’s proprietary, patented, multi-chamber, sequential dose syringe technology.
Sagent said that its dual-chamber syringe enables the sequential administration of two separate intravenous medications with a single syringe push, thereby replacing two syringes with one.
The benefits of this single delivery capability include increasing the speed and ease of drug administration, reducing risk of hospital acquired infection by reducing the number of connections, lowering the risk of drug administration or sequence errors, and quicker delivery of emergency medicines requiring an immediate sequential flush, added Sagent.
The unique dual-chamber syringe can accommodate lyophilized, powder or liquid formulations in the front chamber combined with diluents, saline or heparin flush in the rear chamber, according to Sagent.
Jeffrey Yordon, chairman, founder and CEO of Sagent Pharmaceuticals, said: “We believe that this dual-chamber syringe technology has far reaching benefits which will allow healthcare providers to deliver multiple drugs more quickly and more safely than with multiple syringes. The simplicity and functionality of this device yield near-term opportunities for use with both proprietary and multi-source pharmaceutical products.
“We welcome Infusive’s CEO, Bradley Robinson, to Sagent in his role as president of Sagent’s newly created device division, Sagent Technologies. The creation of Sagent Technologies marks an important milestone for the company, as it enhances our ability to provide a broad range of differentiated product offerings to healthcare providers.”
Comments